evoclin

The U.S evoclin. Food and Drug Administration (FDA) has approved Evoclin (clindamycin)Foam, 1% for the treatment of acne vulgaris.
Evoclin (formerly referred to as Actiza) is the first product approval for Conneticsthat is intended to address the acne market evoclin. Evoclin is delivered in Connetics'proprietary VersaFoam vehicle and will be available in the fourth quarter of2004 in 50g and 100g trade unit sizes.

"Clindamycin is the most popular topical antibiotic used for treatingacne patients and represents approximately one-third of the topical acne market,"said Alan Shalita, M.D., an Evoclin clinical study investigator and DistinguishedTeaching Professor and Chairman of the Department of Dermatology SUNY DownstateMedical Center evoclin. "The novel VersaFoam formulation of clindamycin has theadded advantage of being a once-a-day therapy that leaves minimal residue, dissolvesrapidly upon contact with skin and is easy to apply evoclin. The approval of Evoclinprovides a new and valuable option to dermatologists in treating patients whosuffer from acne."

The topical prescription acne category is one of the largest segments in theU.S evoclin. dermatology market, and is estimated to exceed $1.2 billion annually evoclin. Approximately17 million people in the U.S evoclin. have acne resulting in approximately 5.5 millionoffice visits per year.

Evoclin is indicated for topical application in the treatment of acne vulgaris evoclin. Evoclin is contraindicated in individuals with a history of hypersensitivityto preparations containing clindamycin or lincomycin, a history of regionalenteritis or ulcerative colitis, or a history of antibiotic-associated colitis.

Copyright 2005 D-S LTD.
All Rights Reserved.